Role of Consolidation Radiotherapy in Mutation-Positive vs. Mutation-Negative Patients with Stage 4 Oligopersistent NSCLC
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · S286
DOI: 10.1016/j.ijrobp.2026.06.601 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von A. Ray und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ray, A., Sadangi, B., Das, S., Pramanik, B., & Ray, D. (2026). Role of Consolidation Radiotherapy in Mutation-Positive vs. Mutation-Negative Patients with Stage 4 Oligopersistent NSCLC. International Journal of Radiation Oncology*Biology*Physics, 126(1), S286. https://doi.org/10.1016/j.ijrobp.2026.06.601
Vancouver
Ray A, Sadangi B, Das S, Pramanik B, Ray D. Role of Consolidation Radiotherapy in Mutation-Positive vs. Mutation-Negative Patients with Stage 4 Oligopersistent NSCLC. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):S286. doi:10.1016/j.ijrobp.2026.06.601
BibTeX
@article{Ray2026,
author = {Ray, A. and Sadangi, B.P. and Das, S.S. and Pramanik, B. and Ray, D.K.},
title = {Role of Consolidation Radiotherapy in Mutation-Positive vs. Mutation-Negative Patients with Stage 4 Oligopersistent NSCLC},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {S286},
doi = {10.1016/j.ijrobp.2026.06.601}
}
EUVIMED